Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceftaroline Fosamil

FDA-approved product (powder, intravenous), marketed as Ceftaroline Fosamil, Teflaro.

Registered studies
50+
Lab records
19
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ceftaroline Fosamil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial infectious disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cephalosporins and penems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DI02

Repurposing investigation

Ceftaroline Fosamil is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA75.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli74.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae92.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 13 of 19 lab records
Open Ceftaroline Fosamil in ChEMBL Registered studies below
Show the 19 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftaroline Fosamil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age

    NCT00633126 · start 2008-03

    Registered record
    Registry ID
    NCT00633126
    Conditions
    Infection
    Interventions
    ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-03
    Completion
    2009-02
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    Interventionceftaroline
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

    NCT00633152 · start 2008-02

    Registered record
    Registry ID
    NCT00633152
    Conditions
    Bacterial Infection
    Interventions
    ceftaroline; linezolid; Aztreonam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2008-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection
    Interventionceftaroline; linezolid; Aztreonam
    PhasePhase 2
    Registry statusCompleted

  • Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

    NCT00621504 · start 2008-01

    Registered record
    Registry ID
    NCT00621504
    Conditions
    Bacterial Pneumonia
    Interventions
    Ceftaroline fosamil for Injection; IV Ceftriaxone; Placebo; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-06
    Enrolment
    606

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Pneumonia
    InterventionCeftaroline fosamil for Injection; IV Ceftriaxone; Placebo; Clarithromycin
    PhasePhase 3
    Registry statusCompleted

  • Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

    NCT00423657 · start 2007-03

    Registered record
    Registry ID
    NCT00423657
    Conditions
    Bacterial Infections
    Interventions
    ceftaroline; vancomycin plus aztreonam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2007-12
    Enrolment
    680

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    Interventionceftaroline; vancomycin plus aztreonam; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

    NCT00424190 · start 2007-02

    Registered record
    Registry ID
    NCT00424190
    Conditions
    Bacterial Infections
    Interventions
    IV Vancomycin plus IV Aztreonam; Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-02
    Completion
    2007-11
    Enrolment
    698

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionIV Vancomycin plus IV Aztreonam; Ceftaroline
    PhasePhase 3
    Registry statusCompleted